PE20010053A1 - Formulacion de amoxicilina y clavulanato de potasio - Google Patents

Formulacion de amoxicilina y clavulanato de potasio

Info

Publication number
PE20010053A1
PE20010053A1 PE2000000332A PE0003322000A PE20010053A1 PE 20010053 A1 PE20010053 A1 PE 20010053A1 PE 2000000332 A PE2000000332 A PE 2000000332A PE 0003322000 A PE0003322000 A PE 0003322000A PE 20010053 A1 PE20010053 A1 PE 20010053A1
Authority
PE
Peru
Prior art keywords
amoxicillin
clavulanate
plasma
refers
potassium clavulanate
Prior art date
Application number
PE2000000332A
Other languages
English (en)
Spanish (es)
Inventor
Creighton Conley
Kevin Storm
John Roush
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Publication of PE20010053A1 publication Critical patent/PE20010053A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Peptides Or Proteins (AREA)
PE2000000332A 1999-04-13 2000-04-11 Formulacion de amoxicilina y clavulanato de potasio PE20010053A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
PE20010053A1 true PE20010053A1 (es) 2001-03-10

Family

ID=27383840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000332A PE20010053A1 (es) 1999-04-13 2000-04-11 Formulacion de amoxicilina y clavulanato de potasio

Country Status (44)

Country Link
EP (4) EP1269997A1 (cg-RX-API-DMAC7.html)
JP (2) JP4880125B2 (cg-RX-API-DMAC7.html)
KR (1) KR100634937B1 (cg-RX-API-DMAC7.html)
CN (1) CN100382782C (cg-RX-API-DMAC7.html)
AP (1) AP1806A (cg-RX-API-DMAC7.html)
AR (1) AR031068A1 (cg-RX-API-DMAC7.html)
AT (2) ATE242629T1 (cg-RX-API-DMAC7.html)
AU (1) AU767177B2 (cg-RX-API-DMAC7.html)
BE (2) BE1013309A5 (cg-RX-API-DMAC7.html)
BG (1) BG65006B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0009719B8 (cg-RX-API-DMAC7.html)
CA (1) CA2366304C (cg-RX-API-DMAC7.html)
CO (1) CO5170471A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298801B6 (cg-RX-API-DMAC7.html)
DE (3) DE60003255T2 (cg-RX-API-DMAC7.html)
DK (3) DK200000602A (cg-RX-API-DMAC7.html)
DZ (1) DZ3150A1 (cg-RX-API-DMAC7.html)
EA (1) EA004310B1 (cg-RX-API-DMAC7.html)
ES (2) ES2190692B1 (cg-RX-API-DMAC7.html)
FI (2) FI4823U1 (cg-RX-API-DMAC7.html)
FR (1) FR2792198A1 (cg-RX-API-DMAC7.html)
GB (1) GB2351661B (cg-RX-API-DMAC7.html)
GR (1) GR1003560B (cg-RX-API-DMAC7.html)
HU (1) HU229097B1 (cg-RX-API-DMAC7.html)
IE (1) IE20000271A1 (cg-RX-API-DMAC7.html)
IL (2) IL145580A0 (cg-RX-API-DMAC7.html)
IT (1) ITMI20000788A1 (cg-RX-API-DMAC7.html)
MA (1) MA25352A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010377A (cg-RX-API-DMAC7.html)
MY (1) MY119953A (cg-RX-API-DMAC7.html)
NL (2) NL1014914C1 (cg-RX-API-DMAC7.html)
NO (1) NO329694B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514575A (cg-RX-API-DMAC7.html)
OA (1) OA11926A (cg-RX-API-DMAC7.html)
PE (1) PE20010053A1 (cg-RX-API-DMAC7.html)
PL (1) PL197448B1 (cg-RX-API-DMAC7.html)
PT (2) PT1044680E (cg-RX-API-DMAC7.html)
RO (1) RO120817B1 (cg-RX-API-DMAC7.html)
SE (1) SE0001330L (cg-RX-API-DMAC7.html)
SI (2) SI20304A (cg-RX-API-DMAC7.html)
SK (1) SK285140B6 (cg-RX-API-DMAC7.html)
TR (1) TR200102963T2 (cg-RX-API-DMAC7.html)
TW (1) TWI235067B (cg-RX-API-DMAC7.html)
WO (1) WO2000061116A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DK0862431T3 (da) 1995-09-07 2002-03-11 Smithkline Beecham Plc Anvendelse af pædiatrisk farmaceutisk formulering omfattende amoxycillin og clavulanat
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
WO2003086267A2 (en) * 2002-04-10 2003-10-23 Miller Fred H Multi-phase, multi-compartment capsular system
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
EP2079453A1 (en) * 2006-10-10 2009-07-22 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
WO2016164464A1 (en) * 2015-04-07 2016-10-13 Church & Dwight Co., Inc. Multicomponent gummy compositions with hard core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业(石家庄)有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008905B1 (en) * 1978-09-06 1983-02-16 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP1034784A3 (en) * 1993-01-22 2001-06-27 Smithkline Beecham Plc Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DK0862431T3 (da) * 1995-09-07 2002-03-11 Smithkline Beecham Plc Anvendelse af pædiatrisk farmaceutisk formulering omfattende amoxycillin og clavulanat
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
SK110299A3 (en) * 1997-02-14 2000-08-14 Smithkline Beecham Lab Pharmaceutical formulations comprising amoxocyllin and clavulanate, preparation method and use thereof
SK121099A3 (en) * 1997-03-11 2000-06-12 Almag Al Process and apparatus for coating metals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
ATE286715T1 (de) * 1997-03-25 2005-01-15 Takeda Chemical Industries Ltd Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
PT102450A (pt) 2001-02-01
SE0001330D0 (sv) 2000-04-11
AT4327U1 (de) 2001-06-25
NL1014915A1 (nl) 2000-10-16
MY119953A (en) 2005-08-30
CO5170471A1 (es) 2002-06-27
BR0009719A (pt) 2002-01-08
TR200102963T2 (tr) 2002-02-21
SI20304A (sl) 2001-02-28
FIU20000164U0 (fi) 2000-04-11
BE1012733A6 (fr) 2001-02-06
EP1044680B1 (en) 2003-06-11
WO2000061116A2 (en) 2000-10-19
NO20001870L (no) 2000-10-16
ITMI20000788A1 (it) 2001-10-11
EA200101075A1 (ru) 2002-04-25
DK200000602A (da) 2000-10-14
IL145580A0 (en) 2002-11-10
NO329694B1 (no) 2010-12-06
SE0001330L (sv) 2000-10-14
NZ514575A (en) 2004-05-28
CZ298801B6 (cs) 2008-02-06
HU0001471D0 (en) 2000-06-28
JP4880125B2 (ja) 2012-02-22
EP1270005A2 (en) 2003-01-02
IL145580A (en) 2007-05-15
DE10017883A1 (de) 2000-10-26
HUP0001471A3 (en) 2001-10-29
JP2002541187A (ja) 2002-12-03
PT102450B (pt) 2003-09-30
ES2190692B1 (es) 2004-11-16
GB2351661B (en) 2001-10-10
SK5342000A3 (en) 2000-11-07
AR031068A1 (es) 2003-09-10
DK1044680T3 (da) 2003-09-29
RO120817B1 (ro) 2006-08-30
FI20000863A7 (fi) 2000-10-13
KR20020015312A (ko) 2002-02-27
DZ3150A1 (fr) 2000-10-19
CN100382782C (zh) 2008-04-23
WO2000061116A3 (en) 2001-02-01
BG104329A (en) 2001-11-30
HU229097B1 (en) 2013-07-29
CN1382040A (zh) 2002-11-27
EP1269996A1 (en) 2003-01-02
CA2366304A1 (en) 2000-10-19
GB2351661A (en) 2001-01-10
ATE242629T1 (de) 2003-06-15
ES2190692A1 (es) 2003-08-01
EP1270005A3 (en) 2006-05-17
BG65006B1 (bg) 2006-12-29
AU767177B2 (en) 2003-11-06
BRPI0009719B8 (pt) 2021-05-25
PT1044680E (pt) 2003-10-31
NL1014914C1 (nl) 2000-10-16
FI20000863A0 (fi) 2000-04-11
NO20001870D0 (no) 2000-04-11
PL339591A1 (en) 2000-10-23
DE20006626U1 (de) 2000-10-19
MXPA01010377A (es) 2002-10-23
CA2366304C (en) 2004-06-29
IE20000271A1 (en) 2001-04-04
DE60003255D1 (de) 2003-07-17
AP1806A (en) 2007-12-14
SI1044680T1 (en) 2003-12-31
FR2792198A1 (fr) 2000-10-20
TWI235067B (en) 2005-07-01
AU5702000A (en) 2000-11-14
FI20000863L (fi) 2000-10-13
EA004310B1 (ru) 2004-02-26
NL1014915C2 (nl) 2001-02-12
EP1269997A1 (en) 2003-01-02
OA11926A (en) 2006-04-12
DE60003255T2 (de) 2004-05-06
EP1044680A1 (en) 2000-10-18
KR100634937B1 (ko) 2006-10-17
HK1032741A1 (en) 2001-08-03
DK200000133U3 (da) 2000-07-28
HUP0001471A2 (en) 2001-03-28
GR1003560B (el) 2001-03-16
CZ20001311A3 (cs) 2000-11-15
MA25352A1 (fr) 2001-12-31
ITMI20000788A0 (it) 2000-04-11
AP2001002284A0 (en) 2001-12-31
GB0008923D0 (en) 2000-05-31
BE1013309A5 (fr) 2001-11-06
BR0009719B1 (pt) 2014-09-30
FI4823U1 (fi) 2001-02-16
JP2011256180A (ja) 2011-12-22
ES2202004T3 (es) 2004-04-01
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07

Similar Documents

Publication Publication Date Title
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
DE69907977D1 (de) Pyrrolobenzodiazepine
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
LU91854I2 (fr) Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)
AR027065A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
YU47204B (sh) Derivati didehidro-vitamina d3
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
KR100263496B1 (ko) 탁솔 유도체 및 이의 제조방법
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
SE9504661D0 (sv) New compounds
BRPI0413588A (pt) sistema de branqueamento de dentes, método de branqueamento da superfìcie de um dente, e, kit de branqueamento de dentes
PE20050066A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
DE60004793D1 (de) Echinocandin-kohlenhydrate-komplexe
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
DK1142573T3 (da) Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen
PE3096A1 (es) Formulacion conteniendo selenio
ATE259813T1 (de) Triazolopyrimidinderivate
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
EE200100066A (et) Naatriumkloriidi kasutamine kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsetekõrvaltoimete vähendamiseks
UY26498A1 (es) Pirroles sustituidos

Legal Events

Date Code Title Description
FC Refusal